Armata Pharmaceuticals, Inc. 8-K

What Happened
Armata Pharmaceuticals, Inc. (ARMP) announced on May 7, 2026, that the U.S. Food and Drug Administration granted Fast Track Designation to AP-SA02, the company’s intravenously administered multi‑phage product candidate. The designation covers AP-SA02 as an adjunct treatment for complicated bacteremia caused by methicillin‑sensitive S. aureus (MSSA) or methicillin‑resistant S. aureus (MRSA). The company furnished the related press release as Exhibit 99.1 to its Form 8‑K (Item 7.01 Regulation FD Disclosure).

Key Details

• Date filed: May 7, 2026 (Current Report on Form 8‑K).
• Product: AP‑SA02, an IV multi‑phage candidate targeting Staphylococcus aureus.
• Indication: Adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
• Regulatory action: FDA granted Fast Track Designation; press release furnished as Exhibit 99.1.

Why It Matters
Fast Track is an FDA program meant to facilitate development and speed review for therapies addressing serious conditions and unmet medical needs. For investors, the designation can mean more frequent communications with the FDA and potential eligibility for rolling review or other expedited review mechanisms — steps that may help accelerate clinical development timelines, though it is not an approval and does not guarantee regulatory success. This is a material regulatory milestone for Armata’s AP‑SA02 development program.